RT Journal Article
SR Electronic
T1 Stigma from medication use: an under recognised burden of care
JF Breathe
JO Breathe
FD European Respiratory Society
SP 210002
DO 10.1183/20734735.0002-2021
VO 17
IS 1
A1 Sonal Kansra
A1 Rachel Calvert
A1 Steve Jones
YR 2021
UL http://breathe.ersjournals.com/content/17/1/210002.abstract
AB Children with respiratory diseases take treatments for the self-management of symptoms and to maintain disease control. Often, these treatments need to be taken in social environments like school. Respiratory treatments can foster a feeling of difference and stigmatisation, which negatively impact on the quality of life and adherence to treatment. Such perceptions can lead to a less than optimal disease control, a vicious cycle leading to further social exclusion and stigma. This aspect of “burden of treatment” is poorly recognised by clinicians. Recognition of how treatments and clinical practice can contribute to stigma, can help address this burden of care.Educational aimsTo understand the meaning of the term “stigma” within the context of respiratory health conditions and how medication or treatments can contribute to stigma in children and young people.To understand the potential impact of stigma on adherence, disease control and quality of life.To consider strategies to manage the stigma associated with health treatments across spheres of influence.Children with respiratory diseases take treatments for self-management and to maintain disease control in social environments. These can foster a feeling of difference and being stigmatised which negatively impacts on quality of life and adherence. https://bit.ly/3vV7840